| Filed On | Filing |
|---|---|
| 27 Oct 2026 |
8-K: Results of Operations and Financial Condition
Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Dosing underway in Phase 2a multidose portion of the INLIGHTTM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m2) and comorbidities; trial will also inform WVE-007’s potential in MASH, type 2 diabetes, a... |
| 26 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
As previously announced, in order to complete the redomiciliation of Wave Life Sciences Ltd., a public company limited by shares incorporated under the laws of the Republic of Singapore (“Wave-Singapore”), the board of directors of Wave-... |
| 18 May 2026 |
8-K: Regulation FD Disclosure; Other Events
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing |
| 28 Apr 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, with and without type 2 diabetes, this portion of the trial remains on track to initiate in 2Q ... |
| 21 Apr 2026 |
8-K: Other Events
CAMBRIDGE, Mass., April 21, 2026 – As previously announced, Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, is seeking sha... |
| 15 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
WAVE LIFE SCIENCES, INC., a company incorporated under the laws of Delaware and having its registered office at 1209 Orange Street, Wilmington, DE 19801, U.S.A. (“Wave-Delaware”); and |
| 26 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007 |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while preserving muscle mass |
| 02 Feb 2026 |
8-K: Other Events
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Exhibit 99.2 Wave Life Sciences Corporate Presentation January 12, 2026 |
| 11 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
Introductory. Wave Life Sciences Ltd. (Company Registration Number: 201218209G), a company incorporated under the laws of the Republic of Singapore (the “Company”), proposes to issue and sell to the several underwriters named in Schedule... |
| 08 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss |
| 17 Nov 2025 |
8-K: Regulation FD Disclosure
Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of opera... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding levels that led to weight loss an... |
| 29 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day |
| 24 Sep 2025 |
8-K: Regulation FD Disclosure
Exhibit 99.1 Wave Life Sciences Corporate Presentation September 24, 2025 |
| 03 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency |
| 11 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
1.1 General Purpose. The name of this plan is the Wave Life Sciences Ltd. 2021 Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (i) provide eligible Employees, Consultants, and Directors with the opportunity to acquire... |
| 05 Aug 2025 |
8-K: Regulation FD Disclosure
Exhibit 99.1 Wave Life Sciences Corporate Presentation August 5, 2025 |
Loading...